RA Capital Management MNPR Position
Active4-Fund ConvergenceRA Capital Management increased their position in Monopar Therapeutics (MNPR) in Q4 2025, holding $43.6M worth of shares across 667,207 shares.
The position was first reported in Q4 2024 and has been tracked across 5 quarterly 13F filings.
MNPR is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 65.8% of float with 9.6 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Full company profile →Short Interest
65.8%
9.6 days to cover
RA Capital Management MNPR Position History
Frequently Asked Questions
Does RA Capital Management own MNPR?
Yes. As of Q4 2025, RA Capital Management holds 667,207 shares of Monopar Therapeutics (MNPR) valued at $43.6M. This data comes from their SEC 13F filing.
How many hedge funds own MNPR?
4 specialist biotech hedge funds currently hold MNPR, including Deerfield Management, Deep Track Capital, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy MNPR?
RA Capital Management's position in MNPR was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's MNPR position increasing or decreasing?
RA Capital Management increased their MNPR position in the most recent quarter, adding 156,000 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MNPRCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →